Stockscreener 앱 받기
99.21
1.45%
1.42
시간 외 거래:
99.21
Insmed Inc 주식(INSM)의 최신 뉴스
Insmed IncorporatedLaunches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases - TradingView
Insmed launches four phase 3 trials for lung disease therapy By Investing.com - Investing.com Canada
Three trials have started for Insmed's inhaled treatment; a fourth is expected in the first half of 2027. - Stock Titan
Insmed Incorporated (INSM) Options Chain - Yahoo! Finance Canada
Three presentations will examine an inhaled treatment being studied for high blood pressure in the lungs. - Stock Titan
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $169 to $220 - Moomoo
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM) - The Globe and Mail
Insmed Shares Fall After Wolfe Research Downgrade - Yahoo Finance
Wolfe Research Downgrades Insmed to Peer Perform From Outperform - Moomoo
Truist previews biotech earnings with focus on Insmed, BridgeBio By Investing.com - Investing.com Canada
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
BofA cuts Insmed stock price target on valuation concerns By Investing.com - Investing.com India
Weekly Recap: ARIKAYCE sNDA Jan 28, 2027 FDA date and CFO Bonstein exit - TradingView
Wolfe Research Downgrades Insmed to Peer Perform From Outperform - Yahoo Finance
US High Growth Tech Stocks Spotlight Featuring 3 Top Picks - Simply Wall Street
UBS reiterates Insmed stock rating on Brinsupri sales outlook - Investing.com
Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative? - Yahoo Finance
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - Zacks Investment Research
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - TradingView
Bonstein to step down as Insmed chief financial officer - ROI-NJ
$100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Benzinga
Insmed Announces CFO Transition - Insmed Incorporated Investor Relations
Insmed stock falls as CFO Sara Bonstein to step down - Investing.com
Why is Insmed stock sliding today? By Investing.com - Investing.com India
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed - Benzinga
Insmed stock falls as CFO Sara Bonstein to step down - Yahoo Finance
Insmed drops as investors weigh CFO departure despite reaffirmed 2026 outlook - Quiver Quantitative
Insmed Incorporated Announces Sara Bonstein Steps Down as Chief Financial Officer, Effective October 30, 2026 - marketscreener.com
Insmed Incorporated Reaffirms Earnings Guidance for the Full-Year 2026 - marketscreener.com
Insmed Q2 2026 Earnings Call Transcript - Benzinga
Insmed CFO Sara Bonstein to step down, reaffirms guidance - TradingView
Insmed CFO Sara Bonstein to step down on October 30 By Investing.com - Investing.com Canada
Insmed CFO Sara Bonstein to step down Oct 30; c... - pluang.com
Insmed CFO Sara Bonstein to Separate, Search Underway for Successor - TradingView
Insmed (INSM) Announces CFO Transition - TradingView
Insmed Announces CFO Transition - Yahoo Finance
INSM5182680 Bond Profile: Coupon and Redemption - TradingView
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance UK
Insmed IncorporatedCommon Stock (Nasdaq:INSM) Stock Quote - FinancialContent
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance UK
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
Total liabilities & shareholders' equities of Insmed Incorporated – HAN:IM8N - TradingView
Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target - Investing.com
Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance Singapore
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Yahoo Finance
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - TradingView
Insmed stock price target maintained at $195 by Mizuho on FDA review - Investing.com Canada
1.74%
자본화:
|
볼륨(24시간):